Veeva Systems Inc is a leading provider of cloud-based software solutions tailored specifically for the global life sciences industry
The company offers a range of products designed to streamline and enhance various aspects of the pharmaceutical and biotech sectors, including research and development, regulatory compliance, and commercial operations. By leveraging advanced technology and data analytics, Veeva enables life sciences organizations to improve their efficiency, accelerate drug development processes, and ensure adherence to regulatory standards, ultimately contributing to better patient outcomes and innovation in healthcare.
Veeva's strong remote work policies are attracting top talent and boosting stock performance, contrasting with JPMorgan's return-to-office mandate amid employee backlash.
What has Wall Street been buzzing about this week? Here is a brief look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Jan. 20-24, 2025.
Let’s dig into the relative performance of Veeva Systems (NYSEVEEV) and its peers as we unravel the now-completed Q3 vertical software earnings season.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at vertical software stocks, starting with Q2 Holdings (NYSEQTWO).
Healthcare software provider Veeva Systems (NASDAQVEEV) reported Q3 CY2024 results topping the market’s revenue expectations, with sales up 13.4% year on year to $699.2 million. The company expects next quarter’s revenue to be around $697.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.75 per share was 10.7% above analysts’ consensus estimates.
